HK5 Antibody

What is Human Kallikrein 5 (hK5) and why are antibodies against it important?

Human Kallikrein 5 (hK5) is a member of the human kallikrein gene family of serine proteases that map to chromosome 19q13.4. It functions as an enzymatically active protein with trypsin-like catalytic activity that can autoactivate. The protein exists in multiple glycosylated forms (approximately 44kDa, 40kDa, 35kDa, and 30kDa), all of which demonstrate enzymatic activity . Antibodies against hK5 are critically important because hK5 has been identified as a potential serum biomarker for breast and ovarian cancer, with elevated levels detected in 69% of ovarian cancer patients and 49% of breast cancer patients compared to almost undetectable levels in healthy individuals .

What is the HK5.3 monoclonal antibody and what does it target?

The HK5.3 monoclonal antibody is a research reagent that specifically recognizes mouse B7RP-1 (also known as B7h, B7-H2, GL50, and ICOS Ligand), a member of the B7 family with a predicted molecular weight of approximately 40 kDa that belongs to the immunoglobulin superfamily. This antibody target (B7RP-1) is expressed on antigen-presenting cells including B cells, monocytes/macrophages, and dendritic cells. The molecule binds to the ICOS molecule (AILIM, CRP-1) expressed by activated T cells, playing an important role in T cell costimulation pathways .

What detection methods can be used with HK5 antibodies?

Detection methods for HK5 antibodies depend on the specific research context:

For anti-hK5 antibodies:

• Sandwich-type microplate immunoassays (ELISA) with time-resolved fluorometric detection have been successfully developed for measuring hK5 in biological fluids, tissue extracts, and serum samples .

• These assays demonstrate high specificity with no cross-reactivity with other homologous kallikreins, achieving a lower detection limit of 0.1 μg/liter and a dynamic range of 0.1-25 μg/liter .

For HK5.3 monoclonal antibody:

• Flow cytometric analysis is the primary validated application, particularly for mouse splenocytes .

• The antibody can be used at concentrations ≤0.125 μg per test for cell samples ranging from 10^5 to 10^8 cells in a 100 μL final volume .

How can researchers optimize HK5.3 antibody performance in flow cytometry experiments?

Optimizing HK5.3 antibody performance in flow cytometry requires careful consideration of multiple parameters:

• Titration Protocol:

  • Begin with the recommended concentration (≤0.125 μg per test) but perform careful titration experiments to determine optimal signal-to-noise ratio for your specific cell populations .

  • Test multiple concentrations using a fixed cell number (typically 10^6 cells) to establish the minimum saturating concentration.

• Sample Preparation Considerations:

  • When working with mouse splenocytes, fresh isolation and proper red blood cell lysis are critical for reducing background and optimizing detection.

  • Control for potential autofluorescence by including unstained controls and fluorescence-minus-one (FMO) controls.

• Instrument Settings:

  • The PE-conjugated HK5.3 antibody has an excitation range of 488-561 nm and emission of 578 nm, compatible with blue, green, and yellow-green lasers .

  • Optimize PMT voltages for the PE channel to ensure appropriate detection without saturation.

• Cell Concentration Range:

  • While the antibody can be used with cell numbers ranging from 10^5 to 10^8 cells per test, empirical determination of optimal cell concentration is recommended for each experimental system .

What are the enzymatic properties of hK5 and how do they impact antibody development?

Human Kallikrein 5 demonstrates several distinct enzymatic properties that must be considered when developing antibodies against it:

• Autoactivation Capability:

  • hK5 has been shown to autoactivate, converting from pro-hK5 to active hK5 without requiring external proteolytic processing .

  • This property means antibodies must be carefully designed to distinguish between pro-forms and active forms if such discrimination is experimentally relevant.

• Substrate Specificity:

  • hK5 exhibits trypsin-like catalytic activity with preference for Arginine over Lysine at the P1 position.

  • This is evidenced by its higher activity against substrates like Gly-Pro-Arg-AMC compared to Gly-Pro-Lys-AMC (Kcat/Km = 12 mM⁻¹ × min⁻¹ versus no detectable activity) .

  • The highest enzyme activity was observed with Val-Pro-Arg-AMC and Phe-Ser-Arg-AMC substrates (Kcat/Km = 946 and 877 mM⁻¹ × min⁻¹ respectively) .

• Inhibitor Interactions:

  • hK5 forms stable complexes with α2-antiplasmin (a2-AP) and antithrombin III (ATIII) with inhibition constants (Ki) of 53nM and 69nM respectively .

  • Benzamidine inhibits hK5 with Ki = 188nM .

  • α1-antitrypsin (AAT) and α1-antichymotrypsin (ACT) do not inhibit hK5 .

  • These inhibitor interactions must be considered when developing immunoassays to avoid potential epitope masking.

• Glycosylation Pattern:

  • hK5 exists in multiple glycosylated forms (44kDa, 40kDa, 35kDa, 30kDa), which reduce to a single 28kDa band after N-glycosidase F treatment .

  • Antibodies must be validated against these different glycoforms to ensure consistent detection regardless of glycosylation state.

How should researchers design an ELISA for detecting hK5 in clinical samples?

Designing an effective ELISA for hK5 detection in clinical samples requires careful consideration of multiple methodological aspects:

• Antibody Selection and Format:

  • A sandwich-type microplate immunoassay using polyclonal anti-hK5 antibodies from different species (mouse and rabbit) has proven effective .

  • This approach helps ensure target specificity while maximizing detection sensitivity.

• Detection System:

  • Time-resolved fluorometric detection techniques have demonstrated superior performance for hK5 quantification compared to traditional colorimetric methods .

  • These systems provide a lower detection limit of 0.1 μg/liter and dynamic range of 0.1-25 μg/liter with excellent precision (within-run and between-run CV <10%) .

• Sample Type Considerations:

  • hK5 detection varies significantly by sample type, with highest expression observed in skin, breast, salivary gland, and esophagus tissues .

  • Milk from lactating women contains relatively high levels of hK5 .

  • Serum levels are typically very low in healthy individuals but elevated in certain cancer patients .

• Quality Control Parameters:

  • Include calibration standards spanning the full dynamic range (0.1-25 μg/liter).

  • Incorporate known positive controls (e.g., breast cancer patient serum samples or milk from lactating women).

  • Include specificity controls to verify absence of cross-reactivity with other kallikrein family members.

What purification strategies are effective for producing recombinant hK5 to develop anti-hK5 antibodies?

Effective purification of recombinant hK5 for antibody development involves several critical steps:

• Expression System Selection:

  • The Pichia pastoris yeast expression system has been successfully employed for pro-hK5 production .

  • This eukaryotic system enables proper protein folding and post-translational modifications that may be critical for generating antibodies recognizing native epitopes.

• Purification Protocol:

  • A two-step purification procedure has been documented as effective for hK5 .

  • While specific details of this procedure were not fully elaborated in the search results, typical approaches for secreted proteins from P. pastoris include:
    a) Initial capture using ion exchange chromatography
    b) Polishing step using size exclusion or affinity chromatography

• Quality Assessment:

  • Verify purified protein identity using mass spectrometry .

  • Confirm enzymatic activity using casein and gelatin zymographs .

  • Assess glycosylation status and heterogeneity before immunization.

• Immunization Strategy:

  • Both mouse and rabbit polyclonal anti-hK5 antibodies have been successfully generated using purified recombinant hK5 as the immunogen .

  • These antibodies can then be employed in developing sandwich-type immunoassays with high specificity and sensitivity.

How should researchers interpret varying hK5 levels in different cancer patient populations?

Interpreting hK5 levels in cancer patients requires careful consideration of several factors:

• Cancer Type Variation:

  • Research indicates significant variations in hK5 elevation patterns between cancer types, with detection in approximately 69% of ovarian cancer patients and 49% of breast cancer patients .

  • These differential patterns suggest cancer-specific mechanisms of hK5 regulation that warrant further investigation.

• Reference Range Establishment:

  • Healthy individuals (both male and female) typically show almost undetectable serum hK5 levels .

  • This creates a clear baseline against which to interpret elevations in cancer patients.

• Sample Source Considerations:

  • hK5 levels vary substantially between different biological samples even within the same patient:

    • Elevated in serum of certain cancer patients

    • High concentrations in ascites fluid from metastatic ovarian cancer patients

    • Detectable in ovarian cancer tissue extracts

  • Multi-sample analysis may provide more comprehensive diagnostic information.

• Interpretation Framework:

  • Consider hK5 as part of a biomarker panel rather than in isolation, as it is part of the kallikrein family with several members implicated in cancer.

  • Longitudinal monitoring may provide more valuable clinical information than single time-point measurements.

What factors could cause false positive or false negative results when using HK5.3 antibody in flow cytometry?

Several factors can contribute to misleading results when using HK5.3 antibody for flow cytometry:

• False Positive Causes:

  • Non-specific binding to Fc receptors on cells expressing FcγR (particularly relevant for mouse splenocytes)

    • Solution: Include appropriate Fc blocking reagents in staining protocol

  • Insufficient washing after antibody incubation

    • Solution: Implement more stringent washing steps

  • Spectral overlap from other fluorophores

    • Solution: Perform proper compensation using single-stained controls

• False Negative Causes:

  • Target epitope masking due to processing methods

    • Solution: Optimize fixation protocols or consider using the antibody on unfixed cells

  • Insufficient penetration in intact cells

    • Solution: Adjust permeabilization methods if intracellular staining is required

  • Competition with natural ligand (ICOS)

    • Solution: Perform binding inhibition studies to characterize potential interference

  • Suboptimal antibody concentration

    • Solution: Perform careful antibody titration experiments as recommended (≤0.125 μg per test)

• Technical Considerations:

  • The PE fluorophore (emission: 578 nm) used in the HK5.3 conjugate requires appropriate laser excitation (488-561 nm)

  • Ensure instrument setup is optimized for the specific fluorophore properties

How might anti-hK5 antibodies be incorporated into multiplex biomarker panels for cancer detection?

Integrating anti-hK5 antibodies into multiplex cancer biomarker panels represents a promising direction:

What are the emerging applications of studying B7RP-1/B7-H2 using HK5.3 antibody in immuno-oncology research?

The HK5.3 monoclonal antibody targeting B7RP-1/B7-H2 has potential applications in immuno-oncology research:

• T Cell Costimulation Pathway Analysis:

  • The interaction between B7RP-1 (detected by HK5.3) and ICOS plays an important role in T cell costimulation .

  • This pathway could be relevant for understanding tumor immune evasion mechanisms and developing immunotherapeutic approaches.

• Tumor Microenvironment Characterization:

  • Flow cytometric analysis using HK5.3 can help identify and quantify B7RP-1-expressing antigen-presenting cells in the tumor microenvironment.

  • This characterization could reveal potential therapeutic targets or biomarkers for immunotherapy response.

• Investigating Immune Checkpoint Modulation:

  • The ICOS/B7RP-1 axis represents a potential immune checkpoint that could be targeted alongside established checkpoints like PD-1/PD-L1.

  • HK5.3 could facilitate studies exploring combination immunotherapy approaches targeting multiple immune checkpoints.

• Experimental Considerations:

  • Currently, the HK5.3 antibody is validated for mouse studies, potentially limiting direct clinical translation .

  • Research using this reagent would need to establish relevant mouse models that accurately recapitulate human B7RP-1/ICOS biology.